Helix BioPharma Corp. (TSE:HBP – Get Free Report) shares crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$2.27 and traded as low as C$2.15. Helix BioPharma shares last traded at C$2.26, with a volume of 2,624 shares trading hands.
Helix BioPharma Stock Performance
The company has a market capitalization of C$172.61 million, a PE ratio of -32.29 and a beta of 0.42. The firm has a fifty day simple moving average of C$2.27 and a 200-day simple moving average of C$1.83.
Helix BioPharma (TSE:HBP – Get Free Report) last posted its quarterly earnings results on Wednesday, October 29th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$0.31 million for the quarter. As a group, research analysts anticipate that Helix BioPharma Corp. will post -0.11 EPS for the current fiscal year.
Helix BioPharma Company Profile
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
Featured Articles
- Five stocks we like better than Helix BioPharma
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
